-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
2023-07-05
Shijiazhuang Sihua Pharmaceutical Group’s two specifications of pitavastatin calcium tablets have been approved.
On July 4, Shijiazhuang No.4 Pharmaceutical Group obtained drug production registration approvals from the National Medical Products Administration for two specifications—1mg and 2mg—of Pivastatin Calcium Tablets, Class 4 chemical drugs, which are deemed to have passed the consistency evaluation. As of now, the Group has 52 varieties comprising 69 specifications that have either passed or been deemed to have passed the national generic drug quality and efficacy consistency evaluation.
2023-07-05
Shijiazhuang Fourth Pharmaceutical Group Selected for China’s Most Influential List in the Pharmaceutical Industry
On July 3, the 15th China Pharmaceutical Industry Development Summit Forum, hosted by the Pharmaceutical Industry Chamber of the All-China Federation of Industry and Commerce, was held in Harbin. During the conference, the “2022–2023 List of China’s Most Influential Companies in the Pharmaceutical Industry” was released. Shijiazhuang Sihua Pharmaceutical Group was honored with two prestigious awards: being named among the Top 100 Chinese Pharmaceutical Manufacturers and recognized as a Pioneer Enterprise in China’s Independent Pharmaceutical Innovation.
2023-06-30
Shijiazhuang Sihua Pharmaceutical Group’s Tirofiban Hydrochloride Injection Concentrate (15 ml) Has Been Approved.
On June 29, the concentrated solution for intravenous injection of tirofiban hydrochloride (15 ml), submitted by Shijiazhuang Fourth Pharmaceutical Group, received drug production registration approval from the National Medical Products Administration and is deemed to have passed the evaluation of consistency in quality and efficacy for generic drugs. This is the group’s 34th new product approved so far this year.
On the evening of June 27, the 2022 Mishi Conference (China Pharmaceutical and Health Industry Symbiosis Conference), hosted by Minenet, opened in Huzhou, Zhejiang Province. During the conference, the highly anticipated 2022 Top 100 Chinese Pharmaceutical Industry Rankings were released. Shijiazhuang Fourth Pharmaceutical Group was named among the “Top 100 Chinese Chemical Pharmaceutical Enterprises of 2022” thanks to its strong R&D capabilities and market influence, ranking 39th on the list.
28
2023/06
From June 17 to 18, the first Beijing-Tianjin-Hebei Pharmaceutical Innovation and Development Conference, jointly hosted by the Hebei Provincial Pharmaceutical Association, the Beijing Pharmaceutical Association, and the Tianjin Pharmaceutical Association, and co-sponsored by the Chinese Pharmaceutical Association, the Management Committee of the Xiong'an New Area, and the Hebei Provincial Association for Science and Technology, was held in the Xiong'an New Area. Shijiazhuang Siyao Group attended the conference as a co-organizer of the inaugural meeting of the Professional Committee on Intravenous Medication Preparation and Management of the Chinese Pharmaceutical Association, as well as the special seminar on “Rational Drug Use Management and Practice.”
19
2023/06
Recently, good news came from the Shijiazhuang Municipal Administration for Market Regulation: Shijiazhuang Sihua Pharmaceutical Co., Ltd. has been recognized as a “Shijiazhuang City Contract-Abiding and Creditworthy Enterprise for 2021-2022” thanks to its sound corporate credit management system and excellent contract performance and credit standing.
16
2023/06
Gathering talents from all over to drive industrial development. On June 16, the 2023 High-Quality Development Conference for the Greater Health Industry and the 8th China Pharmaceutical R&D & Innovation Summit, jointly hosted by Yaozhi.com and the magazine China Pharmaceutical Industry, were held in Chongqing, the "Mountain City." At the opening ceremony of this summit, the highly anticipated 2023 Ranking Series of China’s Pharmaceutical R&D Strength was officially unveiled. Shijiazhuang Fourth Pharmaceutical Group was listed among the Top 30 in the 2023 China Pharmaceutical R&D Comprehensive Strength Ranking and among the Top 10 in the 2023 China Chemical Pharmaceutical R&D Strength Ranking. Qu Jiguang, Chairman of the Group’s Board of Directors, was honored with the prestigious title of 2023 China Pharmaceutical Innovation Leader.
16
2023/06
Recently, the municipal government issued the “Decision on Awarding the 2022 High-Tech Achievement Implementation Awards.” Two projects, including “Industrialization of the Basic Solution for Hemofiltration and Hemodiafiltration by Shijiazhuang No.4 Pharmaceutical Co., Ltd.,” were awarded third prize in the Municipal High-Tech Achievement Implementation Awards, each receiving a prize fund of 500,000 yuan.
13
2023/06
On June 13, the Class 3 sodium citicoline injection (4 ml: 0.5 g), developed and submitted by Shijiazhuang Fourth Pharmaceutical Group, received drug production registration approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation.
13
2023/06
On June 1, just one day after the approval of tedizolid phosphate for injection, two specifications of urapidil hydrochloride injection—5 ml: 25 mg and 10 ml: 50 mg—submitted by Shijiazhuang Fourth Pharmaceutical Group simultaneously obtained drug production registration approvals from the National Medical Products Administration and are deemed to have passed the consistency evaluation. It is understood that this is the group’s 31st new product approved this year.
02
2023/06
On May 30, the chemical drug of Class 4—Tazobactam Phosphate Injection (200mg)—submitted by Shijiazhuang No.4 Pharmaceutical Group received the Drug Production Registration Approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation. This is the group’s 28th new product approved this year.
30
2023/05
On May 17, the Class 4 chemical drug—Cinacalcet Hydrochloride Tablets (25mg)—submitted by Shijiazhuang Sihua Pharmaceutical Group obtained the drug production registration approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation.
17
2023/05
Shijiazhuang Fourth Pharmaceutical Group has been receiving frequent good news in new product development. On May 12, the group’s application for urapidil was approved by the National Medical Products Administration, officially registering it as an active pharmaceutical ingredient (API) for use in marketed formulations. This marks the group’s eighth newly approved API this year.
13
2023/05
SERVICE HOTLINE
Mobile site
E code
Business license